Podium to Practice: ESMO® 2025 – Lung: ES-SCLC

Podium to Practice: ESMO® 2025 – Lung: ES-SCLC

Podium to Practice: ESMO® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Barbara Melosky

Icon Chair Speaker

Speakers

Dr. Rosalyn Juergens

Dr. Peter Ellis

Studies / Trials Discussed

2762MO – Patterns of disease progression (PD) and efficacy associated with tumour burden from the Phase 3 IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in ES-SCLC

Studies/trials discussed:

2762MO – Patterns of disease progression (PD) and efficacy associated with tumour burden from the Phase 3 IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in ES-SCLC
Tagged